T. Chitnis1, H. Yano1, S. Saxena1, H. Lokhande1, N. Sattarnezhad1, M.C. Manieri1, A. Paul1, F. Saleh1, M. Collins1, B. Glanz1, C. Guttmann1, R. Bakshi1, F. Qureshi2, M. Becich2, R. Osan2, V. Gehman2, H. Weiner1
1Brigham & Women’s Hospital, Harvard Medical School, Boston, MA, 2Octave Bioscience, Menlo Park, CA, United States
Introduction: Serum levels of neurofilament light chain (sNfL) are associated with neurodegeneration in Multiple Sclerosis (MS) and correlate with measurements of disease activity (DA), including the presence of gadolinium enhancing (GAD+) lesions. MS is a complex disease. Many inflammatory and immune-modulated biological pathways associated with neurodegeneration may impact MS pathophysiology. Investigating these pathways, as represented by protein biomarker expression, can provide deeper insights and reveal stronger correlations to radiographic DA than sNfL alone.
N. Sattarnezhad1, S. Saxena1, C. Gonzalez1, H. Lokhande1, B. Glanz1, F. Qureshi2, M. Becich2, R. Osan2, H. Weiner1, T. Chitnis1
1Partners MS Center, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA, 2Octave Bioscience, Menlo Park, CA, United States
Background: Annualized Relapse Rate (ARR) is a useful and quantifiable outcome measurement related to both disease activity and progression in relapsing forms of Multiple Sclerosis (MS). MS is a heterogeneous disease with various phenotypes and with symptoms that can evolve over time. Therefore, multivariate models reflecting multiple biological pathways that are involved in the complex pathophysiology of the disease including inflammation, immune modulation, and neurodegeneration are most likely to correlate strongly with clinical outcome measurements including ARR status.
R. Osan1, F. Qureshi2, M. Becich1, W. Hagstrom3
1Data Science, 2Assay Development, 3Octave Bioscience, Menlo Park, CA, United States
Introduction: Relapsing-Remitting Multiple Sclerosis (RRMS) is a complex and heterogeneous disease, and multiple biological pathways, including inflammation, immune modulation and neurodegeneration are involved in MS pathophysiology. Investigating these pathways, as represented by differential protein biomarker expression in serum, can help inform the development of tools to accurately track disease activity, identify early evidence of relapse, and monitor treatment response.